Memo Therapeutics
Schlieren
About Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $108.8M
- Funding stage: Late Stage Venture
- Last round: Series C (May 2024)
- Website: memo-therapeutics.com
- Phone: +41 44-515-91-40
Industries & Categories
Biotechnology, Collaboration, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/memo-therapeutics-93035 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.